Eli Lilly Stock News

Eli Lilly and Novo Nordisk have seen demand surpass supply of their weight loss drugs. Their revenues have soared thanks to these popular products.

A prognosticator upgraded his recommendation on the healthcare giant. He says it is now worthy of a buy.

The recent uptick in U.S. manufacturing signals a promising trend for the economy. Investor confidence in the economy's stability is reflected in the decreasing odds for a June rate cut, indicating op

Zepound—an Eli Lilly-produced drug that has become a popular alternative to other weight loss drugs such as Wegovy and Ozempic—is facing a shortage in the U.S. of some of its doses because of the

Drugmakers spent big on ads for weight loss and diabetes drugs such as Wegovy and Ozempic. Meanwhile, the FDA approved the first AI diagnostic tool for sepsis.

The latest trading day saw Eli Lilly (LLY) settling at $763.96, representing a +0.45% change from its previous close.

Biotech's next gold rush is weight-loss drugs. There is a dominance of NVO and LLY in this space for now, notes Rahul Jasuja.

What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

Four doses of Eli Lilly's diabetes drug Mounjaro would remain in tight supply through 2024 due to soaring demand, the U.S. Food and Drug Administration's website showed.

Citi analyst Andrew Baum raised his price target on Lilly stock to $895 from $675, citing increased sales expectations for a new drug.

Eli Lilly shares have climbed in the triple digits over the past year, and earnings have soared too. The company sells two of the world's most sought-after products right now: weight-loss drugs.

Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.

Eli Lilly's stock has seen significant growth due to the success of its obesity drug, "Zepbound," but its high valuation and upcoming competition make it less attractive. Amgen, with its obesity candi

The pharmaceutical and e-commerce industries have proven to be resilient places to invest. Eli Lilly is riding a wave of sales from new blockbuster drugs on top of its flagship products.

Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs. Novo Nordisk's Ozempic and Wegovy, as well as El